Drug news
FDA to review tofacitinib(Pfizer) for Rheumatoid Arthritis in August 2012
The FDA has accepted for review the oral JAK inhibitor tofacitinib (CP-690,550) from Pfizer as a treatment for adults with moderately to severely active Rheumatoid Arthritis.The review is expected to take place in August 2012. The drug also is under review by the European Medicines Agency for the same indication. The submissions are based on the results of the ORAL Sync study.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.